HomeProductsBioactive CompoundsGPCR & G Protein TargetsLPL ReceptorSiponimod
Chemical structure of CAS 1230487-00-9

Siponimod

CAS No.1230487-00-9
MDL No.MFCD26142651
MFC29H35F3N2O3
MW516.60
InChI KeyKIHYPELVXPAIDH-HNSNBQBZSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1230487-00-9
Product NameSiponimod

Biological Targets

S1PR1

Associated Conditions

secondary progressive multiple sclerosis·chronic progressive multiple sclerosis·relapsing-remitting multiple sclerosis·multiple sclerosis·dermatomyositis·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.

Journal of neuroinflammation • Vol. 13, Issue 1 • 2016
PMID: 27566665PMC: PMC5002118DOI: 10.1186/s12974-016-0686-4

The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures.

Journal of neuroinflammation • Vol. 13 • 2016
PMID: 26856814PMC: PMC4746808DOI: 10.1186/s12974-016-0494-x

Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems.

Current drug targets • Vol. 17, Issue 16 • 2016
PMID: 26424391DOI: 10.2174/1389450116666151001112710

Sphingosine 1-phosphate receptor modulators in multiple sclerosis.

CNS drugs • Vol. 29, Issue 7 • 2015
PMID: 26239599PMC: PMC4554772DOI: 10.1007/s40263-015-0261-z

Documentation